Companies › Novelwise Pharmaceutical
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NBM-BMX HDAC8 inhibitor | HDAC (class I/II) | Phase 1 | Metastatic Uveal Melanoma; Malignant Neoplasm; Malignant Neoplasm of Brain | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07136181 | NBM-BMX | Phase 1 | Metastatic Uveal Melanoma | Oncology | Mar 2028 |
| NCT06012695 | NBM-BMX | Phase 1 | Malignant Neoplasm | Oncology | May 2028 |
| NCT07569042 | NBM-BMX | Phase 1 | Malignant Neoplasm of Brain | Oncology | Sep 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.